Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels

Creative Commons License

Bakir Ekinci P., Kara E., Er A. G., İnkaya A. Ç., Demirkan K., Uzun Ö.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol.88, no.3, pp.1387-1391, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 88 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.1111/bcp.14953
  • Journal Name: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.1387-1391
  • Lokman Hekim University Affiliated: No

Abstract

Sir, There is a cumulative evidence suggesting COVID-19 victims are prone to COVID-19 associated pulmonary aspergillosis (CAPA). COVID-19 itself and immunomodulatory medications, such as corticosteroids and tocilizumab, compromise the immune system to an extent that opportunistic infections complicate the course further. In this letter, we aimed to highlight the relationship between inflammation and voriconazole trough levels in COVID-19 patients.